{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T11:34:13Z","timestamp":1780054453704,"version":"3.54.0"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,2,24]],"date-time":"2003-02-24T00:00:00Z","timestamp":1046044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Medical Virology"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Influenza and its complications account for substantial morbidity and mortality among young adults and especially among the elderly. In young adults, immunization provides 70\u201390% protection, while among the elderly the vaccine may be only 30\u201340% effective; hence the need for new, more immunogenic vaccines. We compared the safety and immunogenicity of a novel IL\u20102\u2010supplemented liposomal influenza vaccine (designated INFLUSOME\u2010VAC) with that of a commercial subunit vaccine and a commercial split virion vaccine in young adults (mean age 28 years) in the winter of 1999\u20132000. Seventy\u2010three healthy young adults were randomly assigned to be vaccinated intramuscularly with the following: a commercial subunit vaccine (n\u2009=\u200917, group A), INFLUSOME\u2010VAC (n\u2009=\u200936, group B), and a commercial split virion vaccine (n\u2009=\u200920, group C). The three vaccines contained equal amounts of hemagglutinin (\u223c15 \u03bcg each) from the strains A\/Sydney (H3N2), A\/Beijing (H1N1), and B\/Yamanashi. INFLUSOME\u2010VAC induced higher geometric mean HI titers and higher\u2010fold increases in HI titers against all three strains, compared with the two commercial vaccines. In addition, seroconversion rates for the A\/Sydney and B\/Yamanashi strains were significantly higher (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05) compared with the split virion vaccine, and significantly higher for the three strains compared with the subunit vaccine (69\u201397% vs 35\u201365%, <jats:italic>P<\/jats:italic>\u2009\u2264\u20090.02). Moreover, the anti\u2010neuraminidase response was significantly greater (<jats:italic>P<\/jats:italic>\u2009=\u20090.05) in group B vs group A. INFLUSOME\u2010VAC caused mild local pain at the injection site in a significantly higher proportion of the vaccinees (83%). Thus, INFLUSOME\u2010VAC is an immunogenic and safe vaccine in young adults. J. Med. Virol. 69:560\u2013567, 2003. \u00a9 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jmv.10345","type":"journal-article","created":{"date-parts":[[2003,2,25]],"date-time":"2003-02-25T14:03:37Z","timestamp":1046181817000},"page":"560-567","source":"Crossref","is-referenced-by-count":33,"title":["Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME\u2010VAC) in young adults"],"prefix":"10.1002","volume":"69","author":[{"given":"Arie","family":"Ben\u2010Yehuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aviva","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Zeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simcha","family":"Even\u2010Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igal","family":"Louria\u2010Hayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Babai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichria","family":"Zakay\u2010Rones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenia","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yechezkel","family":"Barenholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Kedar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,2,24]]},"reference":[{"key":"e_1_2_1_2_1","unstructured":"Advisory Committee on Immunization Practices.2000.Prevention and control of influenza: recommendations of the MMWR Morb Mortal Wkly Rep49(RR\u20103):1\u201338."},{"key":"e_1_2_1_3_1","first-page":"207","volume-title":"New generation vaccines","author":"Alving CR","year":"1997"},{"key":"e_1_2_1_4_1","first-page":"199","article-title":"Influenzavirus neuraminidase and neuraminidase\u2010inhibition test procedures","volume":"48","author":"Aymard\u2010Henry M","year":"1973","journal-title":"Bull WHO"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00346-6"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00347-8"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00326-7"},{"key":"e_1_2_1_8_1","first-page":"527","volume-title":"Liposome technology","author":"Barenholz Y","year":"1993"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113052"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00140-6"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199105000-00033"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-10-2559"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.37.100183.002525"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00185-6"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90325-E"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)92758-8"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1006\/immu.1994.1022"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00323-5"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(91)90059-F"},{"key":"e_1_2_1_20_1","first-page":"333","volume-title":"The biotherapy of cancers: from immunotherapy to gene therapy","author":"Kedar E","year":"1998"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-199407000-00005"},{"key":"e_1_2_1_22_1","first-page":"531","volume-title":"Vaccines","author":"Kilbourne ED","year":"1999"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.2.786"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(95)00127-M"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(96)00061-8"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.1995.11.921"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)52451-6"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-1157(83)80034-1"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90093-2"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199409223311206"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.16.1769"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(83)91014-5"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0047-6374(96)01809-X"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/0047-6374(94)90016-7"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(98)00390-9"},{"key":"e_1_2_1_36_1","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4049\/jimmunol.88.3.320","article-title":"Application of microtechnique to viral serologic investigation","volume":"88","author":"Sever J","year":"1962","journal-title":"J Immunol"},{"key":"e_1_2_1_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-1981(01)00092-0"},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(88)90640-X"}],"container-title":["Journal of Medical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjmv.10345","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jmv.10345","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T00:37:39Z","timestamp":1700267859000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jmv.10345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2,24]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1002\/jmv.10345"],"URL":"https:\/\/doi.org\/10.1002\/jmv.10345","archive":["Portico"],"relation":{},"ISSN":["0146-6615","1096-9071"],"issn-type":[{"value":"0146-6615","type":"print"},{"value":"1096-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,2,24]]}}}